Mary Ann Gray, PhD

Dr. Gray is the President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm. She currently serves on the boards of five public biotechnology companies: BioAtla, Keros Pharmaceuticals, Palisade Bio, Rapt Therapeutics, and Sarepta Pharmaceuticals. Previously, Dr. Gray served as a Senior Analyst and Portfolio Manager of Federated Kaufmann Fund. Earlier in her career, she was a biotechnology equity research analyst at multiple firms, as well as a senior scientist both at Schering Plough Research and NeoRx Corporation.

Dr. Gray earned a BS from University of South Carolina, and a PhD in Pharmacology from the University of Vermont, where she focused on novel chemotherapeutic agents for the treatment of cancer. She did post-doctoral work at Northwestern University Medical School and Yale University School of Medicine.